Bessemer Group’s Maravai LifeSciences MRVI Stock Holding History

Bessemer Group’s Portfolio MRVI Stock Details MRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6K	Hold	943	–	–	﹤0.01%	2249
2026 Q1	$3K	Hold	943	–	–	﹤0.01%	2323
2025 Q4	$3K	Buy	+943	New	+$3.17K	﹤0.01%	2360
2025 Q1	–	Sell	-460	Closed	-$3K	–	2627
2024 Q4	$3K	Sell	460 -155	-25%	-$997	﹤0.01%	2138
2024 Q3	$5K	Buy	+615	New	+$5.32K	﹤0.01%	1935
2023 Q2	–	Sell	-24	Closed	–	–	2315
2023 Q1	$0	Hold	24	–	–	﹤0.01%	2004
2022 Q4	$0	Sell	24 -27,507	-100%	-$433K	﹤0.01%	2062
2022 Q3	$703K	Sell	27,531 -3,298	-11%	-$82.8K	﹤0.01%	650
2022 Q2	$876K	Hold	30,829	–	–	﹤0.01%	592
2022 Q1	$1.09M	Sell	30,829 -1,562	-5%	-$52.4K	﹤0.01%	460
2021 Q4	$1.36M	Buy	32,391 +12,169	+60%	+$493K	﹤0.01%	410
2021 Q3	$992K	Buy	20,222 +10,248	+103%	+$500K	﹤0.01%	413
2021 Q2	$416K	Buy	9,974 +2,328	+30%	+$90.2K	﹤0.01%	618
2021 Q1	$272K	Buy	+7,646	New	+$253K	﹤0.01%	692

Other funds holding MRVI

GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

1WCM

12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OAM

Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Bessemer Group's MRVI Position: Q2 2026 in Review

Bessemer Group held its Maravai LifeSciences (MRVI) position steady in Q2 2026 at 943 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #2249.

Bessemer Group first reported a position in MRVI in Q1 2021 and has held it in 14 quarters since. The position peaked at $1.36M in Q4 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

Bessemer Group held 943 shares of Maravai LifeSciences worth $6K as of Q2 2026.
Bessemer Group left its Maravai LifeSciences share count unchanged in Q2 2026.
Maravai LifeSciences made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2249 holding.
Bessemer Group first reported a position in Maravai LifeSciences in Q1 2021 and has held it in 14 quarters since.
Bessemer Group's Maravai LifeSciences position peaked at $1.36M in Q4 2021.
178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.